Клинико-социальная эффективность при поддерживающем лечении больных шизофренией арипипразолом (абилифаем): многосторонняя оценка
И. Я. Гурович, Е.Б. Любов, Г. И. Винидиктова et al. · Социальная и клиническая психиатрия · 2009
The article reports about observational investigation concerning comprehensive evaluation of clinical and social efficacy of maintenance treatment with aripiprazole (Abilify) in schizophrenic patients. Material for investigation were 30 patients, aged 34.5±4.0 years, and they were observed during 24 weeks. The patients chosen for investigation were relatively stable and had been on maintenance treatment with other antipsychotics, both conventional (haloperidol etc.) and atypical (zyprexa, rispolept etc.). Indications for aripiprazole were poor tolera-bility for previous medication, or insufficient effect of medication. Therapists took the decisions about change of medication themselves. Effect of treatment was evaluated in comparison with similar collection of data on previous medication during similar period. Instruments used: PANSS, CGI-S, BARS, AIMS, ASC-C, the Scale of Attitude towards Medication, the Checklist for Evaluation of Mental Patients' Social Functioning and their Quality of Life, Euro-Qol-5D and Checklist of Burden of Disease for family members. 26 (86.7%) succeeded in completing this investigation. Side effects on aripiprazole were observed in 10 cases (33.3%), though they were mostly transient and not severe; the extrapyramidal symptoms diminished, as well as hyperprolactinemia, which could be associated with recovery of menstrual cycle, galactorrhea stopped and libido recovered. There was also a tendency towards losing the previously gained body weight. Some patients on aripiprazole showed further development and stabilization of remission, better parameters of social functioning and quality of life, diminished burden of disease for the family members.
Cited by 0 works.